Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1994-12-28
1996-05-14
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3120
Patent
active
055168019
ABSTRACT:
Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexaenoic acid (DHA) or docosapenmenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.
REFERENCES:
patent: 4816483 (1989-03-01), Georgieva et al.
patent: 4855136 (1989-08-01), Horrobin et al.
patent: 5318991 (1994-06-01), Horrobin et al.
Current Opinion in Gastroenterology vol. 8, No. 2, Apr. 1992.
J. Urology vol. 146, No. 1, Jul. 1991 Buck et al "The Protective Role of Eicosapentaenoic Acid . . . ".
J. Urology, vol. 149, No. 4, Apr. 1993 Burgess p. 441A.
J. Urology, vol. 149, No. 4, Apr. 1993 p. 499A Buck.
Horrobin David F.
Reynolds Brenda E.
Henley III Raymond
Scotia Holdings PLC
LandOfFree
Fatty acid treatment for ectopic calcium deposition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fatty acid treatment for ectopic calcium deposition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fatty acid treatment for ectopic calcium deposition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1895986